NEW YORK (360Dx) - BioMérieux announced today it is collaborating with Baxter International to develop technology related to acute kidney injury detection. The firms have agreed to develop biomarkers that will enable rapid identification of AKI and that may also help inform treatment.
Terms of the deal were not disclosed.
BioMérieux will utilize expertise from its Astute Medical business that it acquired last year. Astute has developed an AKI assay, called Nephrocheck, that BioMérieux has been positioning as useful for guiding sepsis treatment.
Mark Miller, CMO at BioMérieux, confirmed in an email that the company will initially focus on developing additional immunoassays for kidney injury.
"The current NephroCheck assay is for determining the risk of AKI in critically ill patients. There are other important unmet medical needs in the field of critical care and kidney injury which we are trying to address together," Miller said.
Baxter, meanwhile, will be able to use the assays in the prevention, diagnosis, and therapy of kidney injury in order to improve patient outcomes in a cost-efficient manner, according to Miller.
"By working with the team at BioMérieux, we’ll be able to combine their expertise in diagnostics with our experience in bringing the latest medical advancements to the ICU," Reaz Rasul, general manager of Baxter’s Acute Therapies business, said in a statement.